EGFR and neoplasm: However, extensive data from clinical trials conducted in the first-line setting showed that approximately 75% of early responders to EGFR blockade undergo tumor progression within 12 months, while 20% of patients are primary resistant and only less than 5% are actually long-time responders (1–5).